1 A baseline transcriptional signature associates with clinical malaria risk in RTS,S/AS01-2 3 vaccinated African children 4 5 Gemma Moncunill<sup>1\*</sup>, Jason Carnes<sup>2£+</sup>, William Chad Young<sup>3+</sup>, Lindsay N. Carpp<sup>3+</sup>, Stephen De 6 7 Rosa<sup>3</sup>, Joseph J. Campo<sup>1,4</sup>, Augusto J. Nhabomba<sup>5</sup>, Maximillian Mpina<sup>6</sup>, Chenjerai Jairoce<sup>5</sup>, Greg Finak<sup>3</sup>¶, Paige Haas<sup>2</sup>¥, Carl Murie<sup>3</sup>, Phu Van<sup>3</sup>, Héctor Sanz<sup>1</sup>, Sheetij Dutta<sup>7</sup>, Benjamin 8 Mordmüller<sup>8€</sup>, Selidji T. Agnandji<sup>8</sup>, Núria Díez-Padrisa<sup>1</sup>, Nana A. Williams<sup>1</sup>, John J. Aponte<sup>1</sup>, 9 Clarissa Valim<sup>9</sup>, Daniel E. Neafsey<sup>10,11‡</sup>, Claudia Daubenberger<sup>12,13‡</sup>, Juliana McElrath<sup>3†</sup>, Carlota 10 Dobaño<sup>1†</sup>, Ken Stuart<sup>2£†</sup>, Raphael Gottardo<sup>3\*†</sup> 11 12 13 14 <sup>1</sup> ISGlobal, Hospital Clínic - Universitat de Barcelona, Rosselló 153, Barcelona, Catalonia, Spain. 15 16 <sup>2</sup> Center for Infectious Disease Research, Seattle, WA, USA. 17 <sup>3</sup> Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 18 USA. 19 <sup>4</sup>Antigen Discovery Inc, Irvine, CA, USA. <sup>5</sup> Centro de Investigação em Saúde de Manhica (CISM), Rua 12, Cambeve, Vila de Manhica, Maputo, 20 21 Mozambique. <sup>6</sup> Ifakara Health Institute. Bagamoyo Research and Training Centre. P.O. Box 74 Bagamoyo, Tanzania. 22 <sup>7</sup> Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA. 23 <sup>8</sup> Institute of Tropical Medicine and German Center for Infection Research, University of Tübingen, 24 25 Tübingen, Germany <sup>9</sup> Department of Global Health, Boston University School of Public Health, Boston, MA, USA. 26

- 27 <sup>10</sup> Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, MA, USA.
- 28 <sup>11</sup> Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- 29 <sup>12</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland.
- 30 <sup>13</sup> University of Basel, Basel, Switzerland.
- These authors contributed equally to this work.
- These authors contributed equally to this work.
- <sup>†</sup> These authors contributed equally to this work.
- 37 Institute, Seattle, WA, USA.

35

42

45

46

- 38 ¶Current affiliation: Ozette Technologies, Seattle, WA, USA.
- 39 \* Current affiliation: Department of Cellular and Molecular Pharmacology, University of California
- 40 San Francisco, San Francisco, CA, USA.
- 41 € Current affiliation: Department of Medical Microbiology, Radboudumc, Nijmegen, Netherlands.
- \*To whom correspondence should be addressed: gemma.moncunill@isglobal.org and
- 44 rgottard@fredhutch.org

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

Abstract In a phase 3 trial in African infants/children, the RTS,S/AS01 (GSK) vaccine showed moderate efficacy against clinical malaria. We aimed to identify RTS,S/AS01-induced signatures associated with clinical malaria by analyzing antigen-stimulated peripheral blood mononuclear cells sampled from a subset of trial participants at baseline and month 3 (one month post-third dose). RTS,S/AS01 vaccination was associated with downregulation of B-cell and monocyte-related blood transcriptional modules (BTMs) and upregulation of T-cell related BTMs, as well as higher month 3 (vs baseline) circumsporozoite protein (CSP)-specific CD4<sup>+</sup> T-cell responses. There were few RTS,S/AS01associated BTMs whose month 3 levels correlated with malaria risk. In contrast, baseline levels of BTMs associated with dendritic cells and with monocytes (among others) correlated with malaria risk. A cross-study analysis supported generalizability of the baseline dendritic cell- and monocyte-related BTM correlations with malaria risk to healthy, malaria-naïve adults, suggesting inflammatory monocytes may inhibit protective RTS,S/AS01-induced responses. Introduction Malaria remains a serious public health problem, with an estimated 229 million cases and 409,000 related deaths in 2019 (1). Despite the strides that interventions such as long-lasting insecticide treated bed nets, improved vector control and diagnostic tests, and mass antimalarial drug administration campaigns have made towards reducing malaria-related morbidity and mortality (2, 3), there is a critical need for an effective malaria vaccine (4, 5). The RTS,S/AS01 malaria vaccine targets the pre-erythrocytic stage of the parasite life cycle and has been designed to elicit strong humoral and cellular immune responses against the *Plasmodium* falciparum circumsporozoite protein (CSP) (6). This recombinant vaccine consists of a protein

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

containing multiple immunodominant NANP repeats and the carboxy terminus of CSP fused to hepatitis B virus surface antigen (HBs) formulated in the AS01 adjuvant (7). In a phase 3 trial in 15,459 African infants and children (Clinical Trials.gov NCT00866619) (8-11), RTS,S/AS01 demonstrated 56% vaccine efficacy (VE) against clinical malaria (follow up time: 12 months post-last dose) in children aged 5-17 months at enrollment and 31% in infants aged 6-12 weeks at enrollment. In 2015, RTS,S/A01 became the first malaria vaccine to receive a positive opinion by the European Medicines Agency under Article 58 (12), and it was recommended by the World Health Organization for a malaria vaccine pilot implementation program in Ghana, Malawi, and Kenya that started in 2019 (13). A critical limitation of the RTS,S vaccine is that VE is moderate (lower in infants than children) and wanes substantially within the first 18 months (10). The identification of immune correlates of protection could help guide iterative vaccine improvements and expedite vaccine evaluation. Excellent work has been done on elucidating correlates of RTS, S/AS01-mediated protection in healthy, malarianaïve adults using the controlled human malaria infection (CHMI) model (14-20), and cohort studies in African infants and children have implicated vaccine-induced anti-CSP antibodies (21-23), as well as CSP-specific Th1 cytokines (24), and CD4<sup>+</sup> T cells (albeit to a lesser extent) in protection in this population (reviewed in (25)). The MAL067 study, an ancillary study to the RTS,S/AS01 phase 3 trial, was conducted to address key knowledge gaps of RTS,S induced immune responses and their correlation with protection against field challenge. Using RNA-sequencing (RNA-seq) data from antigen- or vehicle-stimulated PBMC obtained at baseline and one month post-final dose from infants and children enrolled in Bagamoyo, Tanzania and Manhiça, Mozambique, we aimed to identify baseline and/or RTS,S/AS01-induced signatures associated with clinical malaria risk. Post-vaccination anti-CSP antibody titers, cytokine profiles, and T-cell responses, the latter of which were additionally assessed in samples from

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

participants enrolled in Lambaréné, Gabon, were also examined as correlates of clinical malaria and/or of RTS,S/AS01-induced transcriptional responses. The major finding of our study is that pre-vaccination expression of immune-related blood transcriptional modules (BTMs), including BTMs related to dendritic cells and monocytes, correlated positively with malaria risk in RTS,S/AS01-vaccinated African children; moreover, this dendritic celland monocyte-related signature appeared to be generalizable to malaria-naïve RTS,S/AS01-vaccinated healthy adults. Materials and Methods MAL067 trial During the MAL055 Phase 3 study (Clinical Trials.gov identifier NCT00866619; (11)), infants (6-12) weeks) and children (5-17 months) received RTS,S/AS01 or comparator (rabies vaccine for children; meningococcal C conjugate vaccine for infants), with injections given at month 0 (baseline), month 1, and month 2 (Figure 1). MAL067 was a multi-center immunology ancillary study nested within MAL055 and selection of participants for MAL067 is described in (24). Of the seven trial sites included in MAL067, PBMC samples were collected at baseline (only children) and again at month 3 (one-month post-third dose) at three. The present study analyzes PBMC data from children in Bagamoyo (Tanzania) and from infants and children in Manhiça (Mozambique), as well as from infants and children in Lambaréné (Gabon) (only intracellular cytokine staining (ICS)/immunophenotyping for the latter). All malaria cases with samples collected were included together with 2 to 3 matched nonmalaria controls for each malaria case, prioritizing subjects who had samples at both month 0 and month 3 and in whom the complete set of antigen stimulations was conducted.




Figure 1: Schematic showing vaccination and sampling schedule. Participants received RTS,S/AS01 (or comparator) at month 0, month 1, month 2; peripheral blood mononuclear cells (PBMC) were collected for RNA-sequencing at month 0 and month 3 (1 month post-final dose). Stim, stimulation.

## Case-control definitions

Cases were defined as participants who had any episode of clinical malaria (fever >37.5°C with any parasitemia by blood smear) in the 12 months of follow up after month 3.5, identified by passive case detection (subjects who sought care at a health facility). Controls were participants who did not have any clinical malaria case during the 12 months of follow-up. Controls were matched to cases based on site, age group, and time of vaccination and follow-up. Up to 3 controls were selected for each case

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

among RTS,S/AS01 vaccinees, and 2 controls were selected for each case among comparator vaccinees. PBMC collection and antigen stimulation PBMC collection and stimulation with DMSO (vehicle control), apical membrane antigen (recombinant AMA1, FVO strain), CSP (peptide pools), or HBS (peptide pools) is described in (24)). For stimulation before RNA extraction,  $4x10^5$  freshly isolated PBMC seeded in duplicates were rested for 12 h and then incubated 12 h at 37°C with 1 µg/mL antigens in 96 well-plates. Plates were then centrifuged for 5 min at 250g at room temperature and cell pellet duplicates were resuspended and pooled in RLTbuffer at Bagamoyo or RNAprotect (Qiagen) at Manhiça, transferred into a 96 well Vbottomed plate (Kisker, AttendBio G096-VB) and sealed with adhesive foil (Kisker, Attend Bio G071-P) and cryopreserved at -80°C till RNA extraction. For stimulation before ICS, cryopreserved PBMC were thawed and then rested in a 37°C, 5% CO<sub>2</sub> incubator overnight. PBMC were stimulated for 6 h with the same peptide pools as above, DMSO (vehicle control), and Staphylococcal enterotoxin B as a positive control. Flow immunophenotyping Leftover cryopreserved PBMC thawed for ICS (0.5-1x10<sup>6</sup> cells) were used for leukocyte phenotyping. The flow cytometry panel and staining protocol used is described in (26). Data were acquired using a BD LSR II flow cytometer (BD Biosciences) directly from 96-well plates using a high throughput sampler. Flow cytometry analysis was performed using FlowJo software (Version 9.9 Tree Star). The gating strategy was performed as in (26, 27). *Intracellular cytokine staining* 

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

Antigen-or vehicle-stimulated PBMC were stained using a flow cytometry panel and protocol previously described (27, 28) with the additional marker IL-13. Antibody details can be found in Table S1. Data was acquired and analyzed as above. RNA isolation and sequencing RNA was extracted at the Center for Infectious Disease Research (CIDR, Seattle) using the Promega SV 96 RNA Isolation kit following the manufacturer's protocol. Samples kept in RNAprotect were centrifuged at 4,000g for 7 minutes at 4°C, cell pellets were resuspended in 150 µL RLT Buffer, and 150 μL of 70% ethanol was added prior to processing with Promega SV 96 RNA Isolation kit. RNAs were eluted with 100 μL nuclease free water. Each 96-well extraction batch was spot checked by Bioanalyzer using Agilent RNA 6000 Pico chip and had an average RIN score of 7.4. RNA samples were distributed in 384 well plates for library preparation. Samples from the same individuals were in the same plate and key study variables (vaccine, site and cases-controls) were checked for balance across plates to avoid batch effects. An optimized version of Digital Gene Expression (DGE) was used, further reducing the reverse transcriptase reaction volume. In brief, poly(A)+ mRNA from antigen-stimulated PBMCs was linked to unique molecular identifiers (UMIs) using a template-switching reverse transcriptase. Then, cDNA from multiple cells were pooled, amplified, and prepped for multiplexed sequencing using a transposon-based fragmentation method, enriching for 3' ends and preserving strand information. Nextera XT library preparation and sequence paired-ends were employed on an Illumina NextSeq instrument at the Broad Institute. Immunogenicity data analyzed for correlations with BTM expression Antibody

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

NANP-specific, HBS-specific, and C terminal domain of CSP (C-term)-specific antibody data from previous studies were analyzed for correlations with BTM expression as described below. IgG titers (EU/mL) against NANP and against HBS were obtained from the MAL055 trial database (8-11). IgG titers (EU/mL) against NANP and C-term were measured by ELISA at IAVI-HIL (21). IgG and IgM levels (Median Fluorescence Intensity, MFI) against NANP, C-terminal CSP and HBS together with 35 RTS,S/AS01 vaccine-unrelated malaria antigens were measured by Luminex technology (22, 23). Cellular Data from cytokines in the supernatants of the same CSP and HBS PBMC stimulations analyzed by Luminex in a previous study (24) were used here for detecting BTMs correlated with RTS,S/AS01 immunogenic responses. Data processing and statistical analysis Preprocessing: Preprocessing of RNAseq data was done by Broad Technology Labs. In brief, reads were aligned using BWA Aln version 0.7.10 using UCSC RefSeq (Human 19) with mitochondrial genes added. Quantified samples were then quality controlled using mapping summary statistics to remove low quality samples based on predetermined minimum values for the total number of mapped reads, percent of mapped reads mapped to the human genome, etc. Downstream analysis was applied only to reads that mapped uniquely to a UMI and only mapped to isoforms of the same gene (UMI.unq). Normalization: The TMM normalization method (29) was applied to account for differing number of read counts and to address unwanted technical variation. The voom transformation (30) from the limma R package (31) was applied to standardize and appropriately weight the data for use in linear models.

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

Quality control: In a pilot study, we found that sample libraries that exhibit less than 75,000 total RNAseq reads per sample were of low quality. Thus, such libraries were removed from the study. Genes that had less than 20 samples (around 10%) with read counts greater than 5 were also removed. For further details, see the Supplementary Methods. Differential expression: Differential expression was assessed using module-based (using voom and camera (32)) approaches as implemented in the limma package. Camera, combined with voom, is one of the few gene set enrichment analysis methods that can properly account for inter-gene correlation in RNA-seq data. Specifically, Camera estimates the variance inflation factor for the gene expression that results from inter-gene correlation in the data and incorporates it into test procedures to control the apparent false discovery rate. This step is important since significant correlation is expected among genes in the same module. Inference was based on p-values adjusted for multiple testing by controlling the false discovery rate with the Benjamini-Hochberg (33) method. Differential expression was used to down-select modules constituting the PBMC transcriptional response to RTS,S/AS01 vaccination comparing RTS,S/AS01 vaccinees with comparator at month 3 and pre- and post-RTS,S/AS01E vaccination in children (month 3 vs month 0). Noninformative modules ("TBA") are omitted from all heatmaps. Blood transcriptional module (BTM) analysis: BTMs used were from Li et al. (34). Resulting p-values across BTMs (within stimulation condition) were adjusted for multiple testing with a false discovery rate (FDR) cutoff of 0.2. Only these significant BTMs were tested as candidate immune correlates. BTM correlations with immunogenicity: For each module, a score was calculated for each RTS,S recipient at month 3 and at month 0 based on the average normalized expression level of all genes in the modules, on the log scale. Spearman's rank

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

correlation was used to assess association between gene expression, functional antibody and cellular responses. Each correlation was tested (Pearson correlation test) and a p-value was obtained. P-values were adjusted within each response (across all gene sets); significance was defined as an adjusted pvalue  $\leq 0.2$ . Correlates analysis: We identified BTMs significantly associated with protection using the limma package. The model adjusted for clinical and experimental covariates such as age and technical experimental factors. This model was applied to each BTM and stimulation condition identified in the down-selection process. Resulting p-values were adjusted for multiple testing with an FDR cutoff of 0.2. For the cross-study correlates analysis, BTMs were down-selected based on month 3 or month 0 (as appropriate) data from MAL067 (vehicle-stimulated PBMC only). In brief, month 3 or month 0 data for every BTM were tested and FDR adjustment was done across all BTMs. Only those BTMs with FDR < 0.2 in MAL067 were examined as potential correlates of challenge outcome in the CHMI studies, with FDR adjustment performed within each study. Logistic regression: Conditional logistic regression was applied to assess which monocyte populations were predictive of clinical malaria. The clogit function from the R survival package was used and incorporated a stratified variable which grouped subjects according to a set of personal and clinical factors. Analysis of antigen (Ag)-specific T cells: When analyzing Ag-specific T cells, vehicle-only stimulations (DMSO) were used to determine the effect of Ag stimulation over vehicle stimulation for each PBMC sample. The comparison was performed using the limma package (35) in R as follows:

stimulation\*vaccine, where stimulation = (HBS, AMA1, CSP) vs vehicle and vaccine = RTS,S/AS01 vs Comparator.

## **Results**

Study population and sample collection scheme

PBMC RNA-seq data from a total of 193 participants were analyzed (Table 1). Baseline RNA-seq data were available for 36 recipients (8 cases, 28 controls) and 19 comparator recipients (5 cases, 14 controls), all of whom were children since baseline samples were not collected from infants. Month 3 RNA-seq data were available for 123 RTS,S/AS01 recipients (30 cases, 93 controls) and 70 comparator recipients (23 cases, 47 controls). All (100%) of the participants in Bagamoyo for whom Month 3 RNA-seq data were available were children, whereas nearly all (94.9%) in Manhiça were infants. Table S2 provides similar information for participants for whom immunophenotyping/ICS data were analyzed.

Table 1: Numbers, age group, and case-control status of participants by site for whom PBMC RNA-seq data were available at month 0 and/or at month 3.

Month 0									
Total Participants (Total Participants at Bagomoyo, Total Participants at Manhiça)									
		Cases		Controls					
	Total	Infants	Children	Infants	Children				
RTS,S/AS01	36 (36, 0)	0 (0, 0)	8 (8, 0)	0 (0, 0)	28 (28, 0)				
Comparator	19 (17, 2)	0 (0, 0)	5 (5, 0)	0 (0, 0)	14 (12, 2)				

# Month 3 Total Participants (Total Participants at Bagomoyo, Total Participants at Manhiça)

		Cases		Controls	
	Total	Infants	Children	Infants	Children
RTS,S/AS01	123 (70, 53)	12 (0, 12)	18 (18, 0)	41 (0, 41)	52 (52, 0)
Comparator	70 (45, 25)	6 (0, 6)	17 (16, 1)	15 (0, 15)	32 (29, 3)

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

RTS,S/AS01 vaccination is associated with month 3 downregulation of B cell- and monocyte-related BTMs, along with upregulation of T cell-related BTMs The transcriptional response to RTS,S/AS01 vaccination was assessed in control-stimulated PBMC as well as Ag-stimulated PBMC. Through this approach, we hypothesized that we would see recall responses of Ag-specific T cells activated in vitro, as well as responses of other cell types to the secreted cytokines/chemokines. Of note, the sampling schedule at MAL067 was designed for evaluation of acquired immune responses to the vaccine and not ex vivo responses. Our motivation was that in healthy, malaria-naïve adults, the transcriptional response to RTS,S/AS01 has been shown to largely wane by Week 3 post-final dose (16), implying that the majority of the RTS,S/AS01-induced transcriptional changes in this study likely preceded the month 3 sample collection. Three antigens were chosen for stimulation: CSP (peptides covering the CSP region of RTS,S that encodes B-cell and T-cell epitopes), HBS (peptides covering the HBS, also included in the RTS,S vaccine), and AMA1 (a highly immunogenic antigen expressed briefly on hepatocyte-invading P. falciparum sporozoites and predominantly on red blood cell-invading P. falciparum merozoites, not present in the RTS,S vaccine; included to analyze naturally acquired immunity responses).

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312


313

314

315

Two comparisons were done to characterize the transcriptional response to RTS,S/AS01 vaccination: Comparison (1): comparing gene expression in month 3 samples from RTS,S/AS01 vs comparator recipients (month 3 RTS,S/AS01 vs comparator); and Comparison (2): comparing gene expression in month 3 vs month 0 from RTS,S/AS01 recipients (RTS,S/AS01 month 3 vs month 0). Each comparison has its own advantages: Comparison (1) allows the identification of RTS,S/AS01-specific responses while taking into account other environmental factors to which the children are exposed, such as malaria exposure (albeit malaria transmission intensity was low during the study at both sites). Moreover, the very young ages of the trial participants mean that RTS,S/AS01-induced changes may be confounded with normal developmental changes in participant immune systems, further underscoring the value of Comparison (1), as it does not involve comparison across two different time points. On the other side, an advantage of Comparison (2) is that it takes into consideration each participant's intrinsic baseline gene expression. Comparison (1) uses data from both infants and children, whereas Comparison (2) can only yield insight into RTS,S/AS01 responses in children (as baseline samples were not collected from infants). A BTM-based approach was taken to reduce dimensionality, avoid paying a high penalty for multiple testing, and aid results interpretability. For Comparison (1), there were 59 significantly differentially expressed (FDR cutoff  $\leq 0.2$ ) BTMs across all antigen stimulation conditions (Figure 2, Table S3a). The vast majority (55) of these BTMs were in vehicle-treated PBMCs, with few differences observed in antigen-stimulated PBMCs (0 significantly differently expressed BTMs in CSP-stimulated PBMC and 8 significantly differentially expressed BTMs in AMA1-stimulated PBMC). The categories with the most differentially expressed BTMs were B cells and T cells: In vehicle-stimulated PBMCs from infants/children who received RTS,S/AS01, 11 T cell-related BTMs were upregulated (vs comparator). We also observed that natural killer (NK) cell and mitochondria-related BTMs were upregulated in vehicle-stimulated PBMC, whereas B cell-related BTMs were downregulated. Counter to our initial

expectations, no significant correlations were identified in the CSP-stimulated cells. This result may potentially be explained by the low frequency of CSP-specific T-cells in RTS,S/AS01 vaccinees (e.g. on average, <0.10% of all CD4+ T cells (28)). In AMA1-stimulated cells, surprisingly, the few correlate BTMs that were identified tended to correlate in opposite directions with risk than in the vehicle-stimulated PBMC (i.e. a positive correlate in vehicle-stimulated PBMC yet an inverse correlate in AMA1-stimulated PBMC, and vice versa). We hypothesize that cytokines/chemokines released from activated T cells and their effects on other PBMC may underlie this difference. Alternatively, AMA1 may be eliciting an innate response, which is supported by the findings of Bueno et al. in the context of *P. vivax* (36).



328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

Figure 2: Transcriptional responses and antigen-specific transcriptional responses at one month post-final dose associated with RTS,S/AS01 vaccination. A) Comparison 1: month 3 (M3) PBMC, RTS,S/AS01 vs comparator; B) Comparison 2: M3 PBMC vs. month 0 (M0) PBMC, RTS,S/AS01 recipients only. Cell color intensity represents the strength of the difference in the relevant comparison, expressed as signed log<sub>10</sub> false discovery rate (FDR); blood transcriptional modules (BTMs) with significantly different expression (false discovery rate  $\leq 0.2$ ) between the two compared groups are outlined in black. Red, higher expression in RTS, S/AS01 recipients vs comparator recipients at M3 (Comparison 1) or higher expression in RTS,S/AS01 recipients at M3 vs M0 (Comparison 2); blue, lower expression in RTS,S/AS01 recipients vs comparator recipients at M3 (Comparison 1) or lower expression in RTS,S/AS01 recipients at M3 vs M0 (Comparison 2). High-level BTM annotation groups are shown in the left-most color bar. For Comparison (2), only RTS,S/AS01 recipients for whom month 0 and month 3 samples were available were included in the analysis (i.e., children only). There were 67 significantly differentially expressed (FDR cutoff  $\leq 0.2$ ) BTMs, all in vehicle-stimulated PBMC (Figure 2, Table S3b). Antiviral/interferon (IFN)-, inflammatory/Toll-like receptor (TLR)/chemokine-, dendritic cell-, and transcription-related BTMs were among those upregulated, whereas B cell- and monocyte-related BTMs were among those downregulated. The two Comparisons yielded partially divergent results, likely due to the reasons stated above. However, downregulation of monocyte-related BTMs in vehicle-treated PBMC was consistently observed across the two Comparisons: "Enriched in monocytes (II) (M11.0)" was downregulated in both Comparisons, "Enriched in myeloid cells and monocytes (M81)" was downregulated in Comparison (1), and "Monocyte surface signature (S4)" and "Enriched in monocytes (surface) (M118.1)" were downregulated in Comparison (2). Interestingly, monocyte-related BTMs (including

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

these four BTMs) were upregulated at multiple time-points in response to RTS,S/AS01 administration in (16), pointing to differences between the two study populations. Monocyte-related RTS,S/AS01 signature BTMs associate with clinical malaria risk To preserve statistical power in the immune correlates analysis, only BTMs differentially expressed after RTS,S/AS01 vaccination according to Comparison 1 (any stimulation) were down selected. We define these 59 BTMs as the "RTS,S/AS01 signature BTMs". We next investigated if any of the RTS,S/AS01 signature BTMs were associated with clinical malaria risk in RTS,S/AS01 recipients, by comparing expression of the signature BTMs in cases vs. controls, within each stimulation condition. In vehicle-stimulated PBMC, five BTMs were significantly differently expressed in RTS,S/AS01 cases vs controls (Figure 3, Table S4): "Myeloid cell enriched receptors and transporters (M4.3)" (up), "Respiratory electron transport chain (mitochondrion) (M219)" (down), "Respiratory electron transport chain (mitochondrion) (M238)" (down), "Enriched in myeloid cells and monocytes (M81)" (up), and "Enriched in monocytes (II) (M11.0)" (up). The results suggest a direct correlation of monocyte activity and an inverse correlation of mitochondrial oxidative phosphorylation 1-month post-primary vaccination with clinical malaria risk. The association of monocyte-related BTMs with risk is consistent with studies reporting a positive correlation between monocyte/lymphocyte ratio and clinical malaria risk and/or severity (37, 38).



Figure 3: Associations of month 3 levels of RTS,S/AS01 signature blood transcriptional modules (BTMs) with malaria case status in RTS,S/AS01 recipients. Heatmap showing down-selected signature BTMs (Comparison 1) with significantly different expression [false discovery rate (FDR)  $\leq$  0.2] in month 3 PBMC from RTS,S/AS01 malaria cases vs. non-malaria controls, in at least one stimulation condition. Cell color intensity represents the strength of the difference in the relevant comparison, expressed as signed  $\log_{10}$  FDR; BTMs with significantly different expression in the comparison are outlined in black. Red, higher expression in RTS,S/AS01 cases vs. controls; blue, lower expression in RTS,S/AS01 cases vs. controls. High-level BTM annotation groups are shown in the leftmost color bar.

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

Antigen-stimulated PBMC also showed transcriptional modules associated with clinical malaria risk. However, these results differed largely from those seen in vehicle-stimulated PBMC. The two monocyte-related BTMs (M81, M11.0) that were directly associated with risk in vehicle-stimulated PBMC were inverse correlates in both HBS- and AMA1-stimulated PBMC. Moreover, five T-cell related BTMs were positive correlates of risk in AMA1-stimulated PBMC (Figure 3). The same analysis was performed on comparator recipients (Figure S1). For all five BTMs whose levels in vehicle-stimulated PBMC associated either directly or inversely with risk in RTS,S/AS01 recipients (Figure 3), significant correlations were observed in the opposite direction in comparator recipients (Figure S1), suggesting that positive correlations of the three monocyte-related BTMs with risk and inverse correlations of the mitochondria-related BTMs with risk are specific to RTS,S/AS01 recipients. *Polyfunctional CSP-specific CD4*<sup>+</sup> *T-cell responses* In addition to transcriptional changes, our group has shown previously that RTS,S/AS01 vaccination elicits vaccine-specific antibody and cellular responses in African infants and children (e.g. (21, 23, 28)). The polyfunctionality score is a summary measure that encapsulates a participant's entire Agspecific T-cell response after vaccination (39). Using data from a pilot study of 179 children (none of whom was a malaria case) at the Manhiça and Bagamoyo sites, Moncunill et al. previously showed that MAL067 RTS,S/AS01 recipients have higher month 3 CSP-specific and HBS-specific CD4+ T-cell polyfunctionality scores than comparator recipients (28). Consistent with this finding, we report that average CSP-specific CD4<sup>+</sup> T-cell polyfunctionality and magnitude (frequency of CD4<sup>+</sup> T-cell expressing IL-2 or TNF or CD154) are both higher at month 3 vs. baseline in RTS,S/AS01 vaccine recipients (Figure 4). The few high responders at baseline can likely be attributed to prior malaria

exposure. However, there was no difference in average month 3 CSP-specific T-cell response polyfunctionality or magnitude between RTS,S/AS01 cases vs controls (Figure S2).




Figure 4: RTS,S/AS01 vaccination elicits polyfunctional T-cell responses. Boxplots show A) polyfunctionality score and B) magnitude (% CD4+ T cells expressing IL2 or TNF-α or CD154) of CSP-specific CD4+ T-cell responses in RTS,S/AS01 recipients as assessed by intracellular cytokine staining of PBMC collected at month 0 (M0) or at month 3 (M3). Each dot represents a single participant. Data plotted include all available month 0 and month 3 samples, i.e. paired month 0-month 3 samples were not required for plotting. P values represent two-sample test values.

Month 3 levels of RTS,S/AS01 signature BTMs tend to correlate directly with month 3 IgM antibody responses and inversely with month 3 IgG responses

We next investigated whether month 3 levels of the RTS,S/AS01 signature BTMs were associated with month 3 humoral immune responses in RTS,S/AS01 vaccinees. In vehicle-treated PBMC, both positive and negative associations were seen for multiple antibody variables across functional categories (Figure

426

427

428

429


430

431

432

433

5, Table S5). The three antibody variables whose month 3 levels had the strongest positive correlations with transcriptional data were "IgM, LSA1", "IgM, MSP1 b12 Mad20", and "IgM, MSP6", which tended to be positively correlated with month 3 levels of DC-, inflammatory/TLR/chemokine-, and monocyte-related BTMs. In contrast, month 3 levels of "IgG, AMA1 3D7" and "IgG, AMA1 FVO" tended to be inversely correlated with month 3 levels of DC- and monocyte-related BTMs. None of these associations were seen in comparator recipients (Figure S3), suggesting specificity to RTS,S/AS01 receipt, although we note that sample size is smaller which would have reduced statistical power to detect differences. Month 3 levels of cellular variables assessed by polychromatic flow cytometry did not correlate significantly with the month 3 level of any BTM.



437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

Figure 5: Correlations of month 3 transcriptional and adaptive responses in RTS,S/AS01 vaccine recipients. Heatmap showing correlations between month 3 levels of RTS,S/AS01 signature BTMs and month 3 antibody and cellular responses. Cell color intensity represents the strength of the correlation; BTM/response pairs with significant correlations [false discovery rate (FDR)  $\leq$  0.2] are outlined in black. Cell color represents correlation direction: red, positive correlation; blue, negative correlation. High-level BTM annotation groups are shown in the left-most color bar. The bottom bar denotes the type of adaptive response analyzed (orange, antibody; purple, cellular). Red font: CSPspecific IFN-y responses have been associated with protection against parasitemia in controlled human malaria infection studies (40, 41); corresponding heatmap squares representing significant BTM/response correlations are bordered in red. In Ag-stimulated PBMCs, significant correlations of month 3 levels of both antibody and cellular variables with month 3 BTM levels were also observed (Figure 5, Table S5); as above, the correlations were widely spread across BTM functional groupings. For HBS- and AMA1-stimulated PBMCs, antibody variables with the most correlations included "IgM, LSA1" and "IgM, MSP6". Correlations of month 3 cellular variables with month 3 BTM levels in CSP-stimulated and in HBS-stimulated PBMC were generally positive. Of interest were inverse correlations of month 3 levels of "Resting dendritic cell surface signature (S10)" and "DC surface signature (S5)" with CSP-specific IFN-y responses (which have been associated with protection in CHMI studies (40, 41) and in the MAL067 study (24)). In general, much fewer associations were seen for comparator recipients (Figure S3). Specifically, the inverse associations of CSP-specific IFN-y responses with month 3 levels of DC-related BTMs were not seen, suggesting that these associations are RTS,S/AS01-specific.

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482


483

484

Cross-study immune correlates analysis reveals a mostly consistent association in RTS,S/AS01vaccinees between baseline expression of DC- and monocyte-related BTMs and risk An important question is whether the results of our analysis of the MAL067 trial, which was conducted in African infants and children in malaria-endemic areas, are generally translatable to other study populations. PBMC transcriptomic data are available for at least three different controlled human malaria infection (CHMI) studies conducted in a quite different study population, i.e. healthy, malarianaïve adults in the United States. WRAIR 1032 (NCT00075049) randomly assigned participants to receive RTS,S/AS02A or RTS,S/AS01B at months 0, 1, and 2 (40); MAL068 (NCT01366534) randomly assigned participants to receive Ad35.CS.01 at month 0 followed by RTS,S/AS01B at months 1 and 2 (heterologous prime-boost) or RTS,S/AS01B at months 0, 1, and 2 (14); and MAL071 (NCT01857869) randomly assigned participants to receive a full dose of RTS,S/AS01B at months 0, 1, and 2 or a full dose of RTS, S/AS01B at months 0 and 1, followed by a fractional dose at month 7 (42). Importantly, all these trials share a common vaccine arm: one full dose of RTS,S/AS01B at months 0, 1, and 2 (referred to as the "RRR" arm). Microarray data from WRAIR 1032 were analyzed by Vahev et al. (43), microarray data from MAL068 were analyzed by Kazmin et al. (16), and RNA-seq data from MAL068 and MAL071 were analyzed by Du et al. (17). We performed a cross-study immune correlates analysis where we examined whether the BTMs associated with clinical malaria risk in MAL067 showed similar associations with challenge outcome in each of the three CHMI studies described above. Due to differences in sampling schedules, and the presence of the CHMI challenge (which would complicate results interpretation), we could not compare the exact same month 3 timepoint across studies. We chose instead to compare 21 days postthird dose in MAL068 and in MAL071, i.e. of day of challenge, and 14 days post-third dose in WRAIR 1032, i.e. just before or on day of challenge. We refer to these slightly different post-vaccination time points as "month 3" for simplicity. The month 3 cross-study correlates analysis included BTMs whose month 3 levels (in vehicle-stimulated PBMC) associated with clinical malaria risk in MAL067

RTS,S/AS01B recipients (Figure 3, Table S4) and is shown in Figure 6A. No BTM was consistently associated with malaria risk (or non-protection) across all four studies. The most consistent result was for the monocyte-related BTMs, where month 3 expression of "enriched in monocytes (II) (M11.0)" was significantly associated with risk in 3 of the 4 studies (all except WRAIR 1032), and "enriched in myeloid cells and monocytes (M81)" was significantly associated with risk in MAL067 and MAL071 RRR (Figure 6A, Table S6A).

### A Month 3



#### B Month 0

492

493

494

495

496




Figure 6. Associations of (A) month 3 or (B) month 0 levels of blood transcriptional modules (BTMs) with malaria case status in MAL067 RTS,S/AS01 vaccine recipients across studies sharing a common month 0, month 1, month 2 RTS,S/AS01 arm. A) Heatmap showing the

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

difference in month 3 PBMC BTM expression between RTS,S/AS01 malaria cases vs. non-malaria controls in each of three CHMI studies of the 5 BTMs whose month 3 levels in DMSO-stimulated PBMC associated with malaria case status in MAL067 (Figure 3). Note that "month 3" = 21 days postfinal dose in MAL068 and MAL071, and 14 days post-final dose in WRAIR 1032; we refer to these slightly disparate post-vaccination time points as "month 3" for simplicity. BTMs with significantly different expression [false discovery rate (FDR)  $\leq$  0.2, with adjustment done across the 5 BTMs] are outlined in black. B) Heatmap showing the 35 BTMs whose month 0 levels showed significantly different expression in MAL067 RTS, S/AS01 malaria cases vs. non-malaria controls. These 35 BTMs were also examined as potential correlates of challenge outcome in each of the three CHMI studies. Significantly different expression is defined as FDR  $\leq$  0.2, with adjustment across the 35 BTMs. All data shown are from participants who received the same vaccine regimen: a dose of RTS,S/AS01 at months 0, 1, and 2. MAL067, RNA-seq data from the MAL067 study in African infants and children; WRAIR 1032, Vahey et al. microarray data (43) from the WRAIR 1032 study in malaria-naïve adults (40); MAL068 RRR, RNA-seq data from the RRR arm in the MAL068 study in malaria-naïve adults (14); MAL071 RRR, RNA-seq data from the RRR arm in the MAL071 study in malaria-naïve adults (42). Cell color intensity represents the strength of the difference in the case vs. control comparison, expressed as signed log<sub>10</sub> false discovery rate (FDR); BTMs with significantly different expression (false discovery rate  $\leq 0.2$ ) between the two compared groups are outlined in black. Red, higher expression in RTS,S/AS01 cases vs. controls; blue, lower expression in RTS,S/AS01 cases vs. controls. High-level BTM annotation groups are shown in the left-most color bar. We next performed the baseline correlates analysis of MAL067 (left-most column, Figure 6B). Compared to the results from the month 3 analysis, the baseline correlates analysis of MAL067 revealed a larger number of BTMs whose month 0 levels (in vehicle-stimulated PBMC) associated

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

(nearly all positively) with clinical malaria risk (Figure 6B, Table S6B). These BTMs spanned many functional categories and were related to DCs, inflammation, and monocytes, among other areas. By far the strongest correlation with risk was with "enriched in monocytes (II) (M11.0)" (FDR = 4.74E-9), followed by "inflammatory response (M33)" (FDR = 1.48E-5) and "resting dendritic cell surface signature (S10)" (FDR = 2.69E-4). Comparing across studies, the greatest similarity seemed to be between MAL067 and WRAIR 1032, which shared 26 common BTMs associated with risk; of these, 12 were also associated with risk in MAL068 RRR. Of note, the two functional annotations whose BTMs most consistently associated with risk across these three studies were "Dendritic cells" ("resting dendritic cell surface signature (S10)", "complement and other receptors in DCs (M40)", "DC surface signature (S5)", and "enriched in dendritic cells (M168)" correlated with risk in all three studies) and "Monocytes" ("enriched in monocytes (I)", "enriched in monocytes (II)", "enriched in monocytes "IV", and "monocyte surface signature (S4)" correlated with risk in all three studies). In contrast to the multiple positive baseline transcriptional associations with risk in MAL067, WRAIR 1032, and MAL068 RRR, nearly all the month 0 BTMs that associated with challenge outcome in MAL071 RRR were inversely associated with risk, including all the DC- and monocyte-related BTMs seen in the MAL067 signature. We did not find any obvious differences in study population or in sample collection/processing that could explain the differing results. It is also unknown why we see greater consistency in baseline transcriptional associations with risk across studies vs. month 3 transcriptional associations with risk. Baseline transcriptional associations with month 3 adaptive responses are presented in Figure S4 and Table S7. No significant associations were seen with any antibody responses. Among other functional BTM categories, baseline levels of three monocyte-related BTMs ("Monocyte surface signature (S4)", "enriched in monocytes (II) (M11.0)", and "enriched in myeloid cells and monocytes (M81)"), as well as two dendritic-cell-related BTMs ("resting dendritic cell surface signature (S10)" and "DC surface

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

signature (S5)"), all of which associated with risk in the above analysis, showed significant positive correlations with CSP-specific CD4+ T-cell polyfunctionality score. Monocyte frequencies tend to be higher at baseline and at month 3 in RTS,S/AS01 vaccinees that develop clinical malaria The finding that monocyte-related BTMs were expressed significantly higher in RTS,S/AS01 cases vs controls at month 3 in three of the four studies examined (Figure 6A) and at month 0 in three of the four studies examined (Figure 6B) suggested that monocyte frequencies may be higher in cases vs controls at these two timepoints. To determine if the monocyte-related transcriptional differences in PBMC were reflected in monocyte populations, the frequencies of monocytes in PBMC cases and controls were compared using immunophenotyping and flow cytometry. Figure S5A shows that, when automated gating (44) is performed, monocyte frequencies at month 0 and, to a lesser extent at month 3, tend to be higher in cases than in controls for RTS,S/AS01 and comparator recipients combined. However, these differences were not significant (month 0 p=0.131, month 3 p=0.207). When using manual gating, the inflammatory monocyte frequency and inflammatory monocyte/lymphocyte ratio (Figure S5B, S5C) also appeared to be higher in cases vs controls, at both month 3 and baseline, but again these differences were not significant. Thus, these findings do not support our hypothesis that the monocyte-related transcriptional differences in case vs. control PBMC would be reflected in these monocyte populations in cases vs. controls. A potential explanation for why we identified a baseline monocyte transcriptional signature of risk yet did not see an association of baseline monocyte frequency, inflammatory frequency, or inflammatory monocyte/lymphocyte ratio with risk, is that the baseline monocyte transcriptional signature of risk reflects expression changes in the existing circulating monocyte population, rather than an expansion in the circulating monocyte population.

## Discussion

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

Our main finding is the identification of a baseline blood transcriptional module (BTM) signature, primarily related to dendritic cells, inflammation, and monocytes, that associates with clinical malaria risk in RTS,S/AS01-vaccinated African children. In a cross-study comparison, much of this baseline risk signature – specifically, dendritic cell- and monocyte-related BTMs – was also recapitulated in two of the three CHMI studies in healthy, malaria-naïve adults. Our finding fits into a growing body of evidence that baseline immune status can influence vaccine responses (45). Fourati et al. showed that higher baseline inflammation (as assessed by transcriptomic profiling and flow cytometric analysis of immune cell subset frequencies) was associated with poor antibody response to the hepatitis B vaccine (46). Tsang et al. showed that baseline interferon signaling was robustly correlated with maximum fold change (post-influenza vaccination to baseline) in influenza-specific antibody titer (47). The HIPC Consortium identified a baseline inflammatory gene signature that was associated with higher antibody responses to influenza vaccine in younger participants, yet lower antibody responses in older participants (48). Kotliarov et al. identified baseline transcriptional signatures that predicted antibody responses to the live attenuated yellow fever vaccine and to the trivalent inactivated influenza vaccine (49). Moreover, Hill et al. reported that increased baseline frequencies of plasmablasts and of circulating T follicular helper cells were associated with higher post-RTS,S/AS01 vaccination antibody titers (50). The mechanisms underlying the association found in the present study of baseline monocyte and inflammation-related gene expression with malaria risk in RTS,S/AS01 recipients are unknown, but this association does have potentially important implications, if this association is validated in additional studies of African children in malaria-endemic areas (as our cross-study comparison only looked at CHMI studies in malaria-naïve adults). For instance, an intriguing possibility is that prevaccination administration of anti-inflammatory drugs before vaccine inoculation may potentially reduce baseline inflammation and hence improve RTS,S/AS01-mediated protection. This strategy has been successfully followed in improving antibody responses to the 2012 seasonal influenza vaccine

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

(Agrippal inactivated influenza vaccine) in the elderly (51), albeit it required a 6-week treatment course of the mTOR inhibitor RAD001. While such a treatment course would pose significant logistical challenges in our context, the general approach could potentially become more feasible if new (or existing) anti-inflammatory drugs are found that would require shorter administration periods; there is currently substantial interest towards taking such an approach to improve vaccine response e.g. in older adults (52). The role of inflammatory monocytes in vaccine-immunity is an area of active research, however, the association of monocyte activity with clinical malaria risk is consistent with studies that have reported a positive correlation between monocyte to lymphocyte (ML) ratio and clinical malaria risk and/or severity (37, 38). Of note, the association between clinical malaria risk and ML ratio was found to be independent of both age and antibodies to parasite blood-stage antigens (38). Warimwe et al. reported that the ML ratio modifies the VE of RTS,S, where VE is lower at higher ML ratios (53). The results of Warimwe et al. raised the hypothesis that inflammatory monocytes may inhibit RTS,S-induced protective adaptive responses. Though the setting is different, the findings that monocytes inhibit T cell proliferation (54, 55), T cell activation (55), and B cell responses (56) in various mouse models of viral infection provide a potential basis for this hypothesis. Further studies are needed to determine whether such a inhibitory mechanism is at play in RTS,S vaccine immunity and whether strategies for modulating monocyte populations via chemokine receptor antagonists, as proposed by (55), could help boost RTS,S efficacy. However, here we found that baseline expression of monocyte-related BTMs was positively associated with post-vaccination CSP-specific polyfunctional CD4+ T cell responses. A potential explanation for this association may be more efficient antigen presentation to T cells upon vaccination in individuals with higher baseline expression of these monocyte-related BTMs. The association of month 3 levels of monocyte-related BTMs with risk may be independent from polyfunctional T cells, which we did not find to associate with risk or protection in this work.

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

Our finding of the association of monocyte signatures with malaria risk seem to contradict the results of a recent study in which we found that monocyte BTMs were associated with protection in RTS,S/AS01 vaccinated children and infants (57). However, our previous monocyte-protection association was observed after analyzing gene expression levels in CSP-stimulated, background-corrected (i.e. after subtracting expression in vehicle-stimulated) PBMC (57), whereas the monocyte-risk association described in this study was observed after analyzing gene expression levels in vehicle-stimulated PBMC. Here, we did not detect BTMs associated with the response to RTS,S/AS01 vaccination or with protection when analyzing CSP-stimulated PBMC. This result is not surprising, given the low frequency of CSP-specific T-cells in RTS,S/AS01 vaccinees (e.g. on average, <0.10% of all CD4+ T cells (28)) and the number of T-cell non-responders based on the ICS data reported in this manuscript. In fact, in the previous study we could identify BTMs associated with RTS,S/AS01 vaccination in CSP-stimulated PBMC, but no differentially expressed genes were detected (57) and we had used different stimulation conditions and microarrays instead of RNAseq. It is perhaps counterintuitive – considering that the RTS,S/AS01 vaccine does not contain AMA1 – that we observed a small number of BTMs associated with the response to RTS,S/AS01 vaccination and with clinical malaria risk when analyzing AMA1-stimulated PBMC. To explain this result, we refer the reader to our previous work that showed that RTS,S/AS01 vaccination alters antibody responses to antigens not contained in the RTS,S/AS01 vaccine (22). RTS,S/AS01 recipients received partial protection from the RTS,S/AS01 vaccine, leading possibly to decreased P. falciparum parasite load and/or exposure (infection). We hypothesize that the AMA1 stimulation activated T cells that had been previously primed by prior exposure to P. falciparum and that RTS,S/AS01 recipients had fewer primed T cells due to decreased P. falciparum infection (via partial RTS,S/AS01 protection), providing

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

a potential explanation for the transcriptional differences in AMA1-stimulated PBMC between RTS,S/AS01 vs comparator recipients. We next discuss some limitations of our study. First, in malaria-naïve adults, the transcriptional response to the third RTS,S/AS01 dose has been shown to peak at Day 1 post-injection, with some decline by Day 6 and approximately 90% of the response having waned by Day 21 (16). Therefore, it is likely that the sampling scheme in this study (one month post-final dose) misses the majority of the transcriptional response to RTS,S/AS01. Future studies with dense, early post-vaccination PBMC sampling could be useful for further investigating RTS,S transcriptional immune correlates. Second, PBMCs were stimulated on site and then frozen. As each site performed the procedure separately, this renders our data susceptible to batch effects. However, a standardized SOP and shared reagents were used, decreasing the possibility of such effects. Moreover, an advantage of on-site stimulation of fresh PBMC is that it avoids the decrease in cell viability, and potential loss of detection of Ag-specific cells, that may have occurred if PBMC had been frozen, thawed, and then stimulated at a central location. Third, there was confounding between age and location. As all infants were from Manhiça and the majority of children were from Bagamoyo, it was not possible to examine the impact of age or clinical trial site on RTS,S/AS01 transcriptional response. Fourth, as only patrolling cell subsets are present in PBMC, we were unable to detect potential signals from T cells, B cells, NK cells, and macrophages localized to an infection site including skin and liver or the immune memory compartment localized in secondary lymphoid organs. Despite these limitations, our study also has a number of strengths. For example, while excellent work has already been done to interrogate transcriptional responses to RTS,S/AS01 vaccination in healthy, malaria-naïve adults (including densely sampled early post-vaccination sampling timepoints to capture innate responses) and to identify molecular correlates of RTS,S/AS01-mediated protection against

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

clinical malaria after CHMI in malaria-naïve adults (16, 17, 43, 58), in our study we examined transcriptional responses to RTS,S/AS01 vaccination in infants and children in malaria-endemic areas. This feature is a strength of our study, as 1) infants in particular have relatively immature immune systems (59), making it likely that infants (and younger children) mount different vaccine responses than adults (60); 2) infants and children are especially susceptible to malaria-related morbidity and mortality, making them the target population for this and other malaria vaccines; and 3) continual exposure to P. falciparum, as occurs in endemic areas, influences naturally acquired immunity, which in turn interacts with immunity conferred by RTS,S vaccination (22). Related to this, another advantage of our study is the use of a comparator group which allows to discern the effect of the vaccine from environmental exposures including *P. falciparum* and age. As participants in the study are very young, significant development of their immune systems occurs throughout the duration of the study, meaning that such changes could potentially be confounded with vaccine-induced immune changes. While it will be necessary to perform follow-up studies at more sites and with larger sample sizes to validate the baseline transcriptional signature associated with malaria risk identified here, our study raises interesting hypotheses related to the relationship of inflammation and RTS,S/AS01-mediated protection and suggests potential strategies to explore for augmenting RTS,S/AS01 VE. Acknowledgments We are very grateful to study participants, their families, and vaccine trial site field and lab staff. We thank the Phase 3 trial sites PIs Salim Abdulla, Pedro Alonso, Jahit Sacarlal, and Pedro Aide; the investigators involved in the generation of immunology data used here, including providers of antigens for antibody assays (Itziar Ubillos, Marta Vidal, Alfons Jimenez, Ruth Aguilar, Diana Barrios, Laura

Puyol, Aintzane Ayestaran, Luis Izquierdo, David Cavanagh, James Beeson, David Lanar, Vir

Chauhan, Chetan Chitnis, Deepak Gaur, Evelina Angov, Benoit Gamain, Ross Coppel); the MAL067 Vaccine Immunology Consortium investigators and Working Groups; and Fergal Duffy for valuable comments on the manuscript. We thank GlaxoSmithKline Biologicals S.A. for their support in the conduct of the MAL067 study.

## **Conflicts of interest**

The authors have no conflicts of interest to declare.

## **Funding**

 Funding was obtained from the NIH-NIAID (R01AI095789), NIH-NIAID (U19AI128914), PATH Malaria Vaccine Initiative (MVI), Ministerio de Economía y Competitividad (Instituto de Salud Carlos III, PI11/00423 and PI14/01422). The RNA-seq project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Grant Number U19AI110818 to the Broad Institute. This study was also supported by the Vaccine Statistical Support (Bill and Melinda Gates Foundation award INV-008576/OPP1154739 to R.G.). C.D. was the recipient of a Ramon y Cajal Contract from the Ministerio de Economía y Competitividad (RYC-2008-02631). G.M. was the recipient of a Sara Borrell–ISCIII fellowship (CD010/00156) and work was performed with the support of Department of Health, Catalan Government grant (SLT006/17/00109). This research is part of the ISGlobal's Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces and we acknowledge support from the Spanish Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.

#### References

- 720 1. World Health Organization. World Malaria Report 2020. Available at
- 721 https://www.who.int/publications/i/item/9789240015791 30 Nov 2020. Access date 24 Feb 2021. 2020.
- 722 2. Yang GG, Kim D, Pham A, Paul CJ. A Meta-Regression Analysis of the Effectiveness of
- Mosquito Nets for Malaria Control: The Value of Long-Lasting Insecticide Nets. Int J Environ Res
- 724 Public Health. 2018;15(3).

- 725 3. Eisele TP. Mass drug administration can be a valuable addition to the malaria elimination
- 726 toolbox. Malar J. 2019;18(1):281.
- Healer J, Cowman AF, Kaslow DC, Birkett AJ. Vaccines to Accelerate Malaria Elimination and
- 728 Eventual Eradication. Cold Spring Harb Perspect Med. 2017;7(9).
- 5. Beeson JG, Kurtovic L, Dobano C, Opi DH, Chan JA, Feng G, Good MF, Reiling L, Boyle MJ.
- 730 Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Sci Transl Med.
- 731 2019;11(474).
- 732 6. Hoffman SL, Vekemans J, Richie TL, Duffy PE. The march toward malaria vaccines. Vaccine.
- 733 2015;33 Suppl 4:D13-23.
- 734 7. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG,
- Yuan G, Hollingdale M, Slaoui M, et al. Safety, immunogenicity, and efficacy of a recombinantly
- produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
- 737 J Infect Dis. 1995;171(6):1576-85.
- RTS, S Clinical Trials Partnership. First results of phase 3 trial of RTS, S/AS01 malaria vaccine
- 739 in African children. N Engl J Med. 2011;365(20):1863-75.
- 740 9. RTS, S Clinical Trials Partnership. A phase 3 trial of RTS, S/AS01 malaria vaccine in African
- 741 infants. New England Journal of Medicine. 2012;367(24):2284-95.

- 742 10. RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS, S/AS01 malaria vaccine
- during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young
- 744 infants at 11 African sites. PLoS Med. 2014;11(7):e1001685.
- 745 11. RTS, S Clinical Trials Partnership. Efficacy and safety of RTS, S/AS01 malaria vaccine with or
- 746 without a booster dose in infants and children in Africa: final results of a phase 3, individually
- 747 randomised, controlled trial. Lancet. 2015;386(9988):31-45.
- Hawkes N. European Medicines Agency approves first malaria vaccine. BMJ. 2015;351:h4067.
- 749 13. World Health Organization. Q&A on the malaria vaccine implementation programme (MVIP).
- 750 November 2019. https://www.who.int/malaria/media/malaria-vaccine-implementation-qa/en/ Access
- 751 date Nov 29, 2019.
- 752 14. Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, Paolino K, Moon J,
- Komisar J, Kamau E, Oliver T, Chhoeu A, Murphy J, Lyke K, Laurens M, Birkett A, Lee C, Weltzin
- R, Wille-Reece U, Sedegah M, Hendriks J, Versteege I, Pau MG, Sadoff J, Vanloubbeeck Y, Lievens
- 755 M, Heerwegh D, Moris P, Guerra Mendoza Y, Jongert E, Cohen J, Voss G, Ballou WR, Vekemans J.
- 756 Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in
- 757 Healthy Malaria-Naive Adults. PLoS One. 2015;10(7):e0131571.
- 758 15. Chaudhury S, Ockenhouse CF, Regules JA, Dutta S, Wallqvist A, Jongert E, Waters NC,
- Lemiale F, Bergmann-Leitner E. The biological function of antibodies induced by the RTS,S/AS01
- malaria vaccine candidate is determined by their fine specificity. Malar J. 2016;15:301.
- 761 16. Kazmin D, Nakaya HI, Lee EK, Johnson MJ, van der Most R, van den Berg RA, Ballou WR,
- Jongert E, Wille-Reece U, Ockenhouse C, Aderem A, Zak DE, Sadoff J, Hendriks J, Wrammert J,
- Ahmed R, Pulendran B. Systems analysis of protective immune responses to RTS,S malaria
- vaccination in humans. Proc Natl Acad Sci U S A. 2017;114(9):2425-30.
- 765 17. Du Y, Thompson EG, Muller J, Valvo J, Braun J, Shankar S, van den Berg RA, Jongert E,
- Dover D, Sadoff J, Hendriks J, Gardner MJ, Ballou WR, Regules JA, van der Most R, Aderem A,

- Ockenhouse CF, Hill AV, Wille-Reece U, Zak DE. The Ratiometric Transcript Signature
- 768 MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human
- 769 Malaria Infection. Frontiers in Immunology. 2020;11(669).
- 770 18. Pallikkuth S, Chaudhury S, Lu P, Pan L, Jongert E, Wille-Reece U, Pahwa S. A delayed
- fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper
- and B cell responses. Elife. 2020;9.
- 773 19. Suscovich TJ, Fallon JK, Das J, Demas AR, Crain J, Linde CH, Michell A, Natarajan H,
- Arevalo C, Broge T, Linnekin T, Kulkarni V, Lu R, Slein MD, Luedemann C, Marquette M, March S,
- Weiner J, Gregory S, Coccia M, Flores-Garcia Y, Zavala F, Ackerman ME, Bergmann-Leitner E,
- Hendriks J, Sadoff J, Dutta S, Bhatia SN, Lauffenburger DA, Jongert E, Wille-Reece U, Alter G.
- 777 Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01
- 778 vaccination. Sci Transl Med. 2020;12(553).
- 779 20. Dennison SM, Reichartz M, Abraha M, Spreng RL, Wille-Reece U, Dutta S, Jongert E, Alam
- 780 SM, Tomaras GD. Magnitude, specificity and avidity of sporozoite specific antibodies associate with
- 781 protection status and distinguish among RTS,S/AS01 dose regimens. Open Forum Infectious Diseases.
- 782 2020.
- 783 21. Dobano C, Sanz H, Sorgho H, Dosoo D, Mpina M, Ubillos I, Aguilar R, Ford T, Diez-Padrisa
- N, Williams NA, Ayestaran A, Traore O, Nhabomba AJ, Jairoce C, Waitumbi J, Agnandji ST, Kariuki
- 785 S, Abdulla S, Aponte JJ, Mordmuller B, Asante KP, Owusu-Agyei S, Tinto H, Campo JJ, Moncunill G,
- Gyan B, Valim C, Daubenberger C. Concentration and avidity of antibodies to different
- 787 circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nat Commun.
- 788 2019;10(1):2174.
- 789 22. Dobano C, Ubillos I, Jairoce C, Gyan B, Vidal M, Jimenez A, Santano R, Dosoo D, Nhabomba
- 790 AJ, Ayestaran A, Aguilar R, Williams NA, Diez-Padrisa N, Lanar D, Chauhan V, Chitnis C, Dutta S,
- 791 Gaur D, Angov E, Asante KP, Owusu-Agyei S, Valim C, Gamain B, Coppel RL, Cavanagh D, Beeson

- JG, Campo JJ, Moncunill G. RTS,S/AS01E immunization increases antibody responses to vaccine-
- variety of the variet
- 794 African children: a case-control study. BMC Med. 2019;17(1):157.
- 795 23. Ubillos I, Ayestaran A, Nhabomba AJ, Dosoo D, Vidal M, Jimenez A, Jairoce C, Sanz H,
- 796 Aguilar R, Williams NA, Diez-Padrisa N, Mpina M, Sorgho H, Agnandji ST, Kariuki S, Mordmuller
- 797 B, Daubenberger C, Asante KP, Owusu-Agyei S, Sacarlal J, Aide P, Aponte JJ, Dutta S, Gyan B,
- 798 Campo JJ, Valim C, Moncunill G, Dobano C. Baseline exposure, antibody subclass, and hepatitis B
- response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in
- 800 African children. BMC Med. 2018;16(1):197.
- 801 24. Moncunill G, Mpina M, Nhabomba AJ, Aguilar R, Ayestaran A, Sanz H, Campo JJ, Jairoce C,
- Barrios D, Dong Y, Diez-Padrisa N, Fernandes JF, Abdulla S, Sacarlal J, Williams NA, Harezlak J,
- Mordmuller B, Agnandji ST, Aponte JJ, Daubenberger C, Valim C, Dobano C. Distinct Helper T Cell
- Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees.
- 805 Clin Infect Dis. 2017;65(5):746-55.
- 806 25. Moris P, Jongert E, van der Most RG. Characterization of T-cell immune responses in clinical
- trials of the candidate RTS,S malaria vaccine. Hum Vaccin Immunother. 2018;14(1):17-27.
- 808 26. Moncunill G, Han H, Dobano C, McElrath MJ, De Rosa SC. OMIP-024: pan-leukocyte
- immunophenotypic characterization of PBMC subsets in human samples. Cytometry A.
- 810 2014;85(12):995-8.
- 811 27. Moncunill G, Dobano C, McElrath MJ, De Rosa SC. OMIP-025: evaluation of human T- and
- NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining.
- 813 Cytometry A. 2015;87(4):289-92.
- 814 28. Moncunill G, De Rosa SC, Ayestaran A, Nhabomba AJ, Mpina M, Cohen KW, Jairoce C,
- Rutishauser T, Campo JJ, Harezlak J, Sanz H, Diez-Padrisa N, Williams NA, Morris D, Aponte JJ,
- Valim C, Daubenberger C, Dobano C, McElrath MJ. RTS, S/AS01E Malaria Vaccine Induces Memory

- and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial. Front Immunol.
- 818 2017;8:1008.
- 819 29. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis
- 820 of RNA-seq data. Genome Biol. 2010;11(3):R25.
- 821 30. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis
- tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.
- 823 31. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in
- microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
- 825 32. Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation.
- 826 Nucleic Acids Res. 2012;40(17):e133.
- 827 33. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate a Practical and Powerful
- Approach to Multiple Testing. J R Stat Soc B. 1995;57(1):289-300.
- 829 34. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS,
- Johnson SE, Milton A, Rajam G, Kasturi S, Carlone GM, Quinn C, Chaussabel D, Palucka AK,
- Mulligan MJ, Ahmed R, Stephens DS, Nakaya HI, Pulendran B. Molecular signatures of antibody
- responses derived from a systems biology study of five human vaccines. Nature Immunology.
- 833 2014;15(2):195-204.
- 834 35. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential
- expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
- 836 36. Bueno LL, Fujiwara RT, Soares IS, Braga EM. Direct effect of Plasmodium vivax recombinant
- vaccine candidates AMA-1 and MSP-119 on the innate immune response. Vaccine. 2008;26(9):1204-
- 838 13.
- 839 37. Antwi-Baffour S, Kyeremeh R, Buabeng D, Adjei JK, Aryeh C, Kpentey G, Seidu MA.
- 840 Correlation of malaria parasitaemia with peripheral blood monocyte to lymphocyte ratio as indicator of
- susceptibility to severe malaria in Ghanaian children. Malar J. 2018;17(1):419.

- 842 38. Warimwe GM, Murungi LM, Kamuyu G, Nyangweso GM, Wambua J, Naranbhai V, Fletcher
- 843 HA, Hill AV, Bejon P, Osier FH, Marsh K. The ratio of monocytes to lymphocytes in peripheral blood
- correlates with increased susceptibility to clinical malaria in Kenyan children. PLoS One.
- 845 2013;8(2):e57320.
- Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom
- W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum
- P, Michael NL, Kim JH, Robb ML, O'Connell RJ, Karasavvas N, Gilbert P, S CDR, McElrath MJ,
- 849 Gottardo R. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol.
- 850 2015;33(6):610-6.
- 851 40. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R,
- Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois
- MC, Lievens M, Cohen J, Ballou WR, Heppner DG, Jr., Rts SVEG. Randomized, double-blind, phase
- 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults:
- safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200(3):337-46.
- 856 41. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner
- 857 DG, Krzych U. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium
- falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J
- 859 Immunol. 2003;171(12):6961-7.
- Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK,
- Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M,
- Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson
- WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC,
- Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J. Fractional Third and Fourth Dose
- of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection
- and Immunogenicity Study. J Infect Dis. 2016;214(5):762-71.


- Vahey MT, Wang Z, Kester KE, Cummings J, Heppner DG, Jr., Nau ME, Ofori-Anyinam O,
- 868 Cohen J, Coche T, Ballou WR, Ockenhouse CF. Expression of genes associated with
- immunoproteasome processing of major histocompatibility complex peptides is indicative of protection
- with adjuvanted RTS,S malaria vaccine. J Infect Dis. 2010;201(4):580-9.
- 871 44. Greene E, Finak G, D'Amico LA, Bhardwaj N, Church CD, Morishima C, Ramchurren N,
- Taube JM, Nghiem PT, Cheever MA, Fling SP, Gottardo R. A new data-driven cell population
- discovery and annotation method for single-cell data, FAUST, reveals correlates of clinical response to
- cancer immunotherapy. bioRxiv. 2019:702118.
- 875 45. Tsang JS, Dobano C, VanDamme P, Moncunill G, Marchant A, Othman RB, Sadarangani M,
- 876 Koff WC, Kollmann TR. Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?
- 877 Trends Immunol. 2020;41(6):457-65.
- 878 46. Fourati S, Cristescu R, Loboda A, Talla A, Filali A, Railkar R, Schaeffer AK, Favre D, Gagnon
- D, Peretz Y, Wang IM, Beals CR, Casimiro DR, Carayannopoulos LN, Sekaly RP. Pre-vaccination
- inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat
- 881 Commun. 2016;7:10369.
- Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ,
- Narayanan M, Golding H, Moir S, Dickler HB, Perl S, Cheung F, Baylor HC, Consortium CHI. Global
- analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell.
- 885 2014;157(2):499-513.
- 48. HIPC-CHI Signatures Project Team, HIPC-I Consortium. Multicohort analysis reveals baseline
- transcriptional predictors of influenza vaccination responses. Sci Immunol. 2017;2(14).
- 888 49. Kotliarov Y, Sparks R, Martins AJ, Mule MP, Lu Y, Goswami M, Kardava L, Banchereau R,
- Pascual V, Biancotto A, Chen J, Schwartzberg PL, Bansal N, Liu CC, Cheung F, Moir S, Tsang JS.
- Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy
- individuals and disease activity in patients with lupus. Nat Med. 2020;26(4):618-29.

- 892 50. Hill DL, Carr EJ, Rutishauser T, Moncunill G, Campo JJ, Innocentin S, Mpina M, Nhabomba
- A, Tumbo A, Jairoce C, Moll HA, van Zelm MC, Dobano C, Daubenberger C, Linterman MA.
- 894 Immune system development varies according to age, location, and anemia in African children. Sci
- 895 Transl Med. 2020;12(529).
- 896 51. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA,
- 897 Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB. mTOR inhibition improves immune
- 898 function in the elderly. Sci Transl Med. 2014;6(268):268ra179.
- 899 52. Pereira B, Xu XN, Akbar AN. Targeting Inflammation and Immunosenescence to Improve
- Vaccine Responses in the Elderly. Front Immunol. 2020;11:583019.
- 901 53. Warimwe GM, Fletcher HA, Olotu A, Agnandji ST, Hill AV, Marsh K, Bejon P. Peripheral
- blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria
- 903 vaccine: analysis of pooled phase II clinical trial data. BMC Med. 2013;11:184.
- 904 54. Norris BA, Uebelhoer LS, Nakaya HI, Price AA, Grakoui A, Pulendran B. Chronic but not
- acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-
- 906 specific T cell immunity. Immunity. 2013;38(2):309-21.
- 907 55. Mitchell LA, Henderson AJ, Dow SW. Suppression of vaccine immunity by inflammatory
- 908 monocytes. J Immunol. 2012;189(12):5612-21.
- 909 56. Sammicheli S, Kuka M, Di Lucia P, de Oya NJ, De Giovanni M, Fioravanti J, Cristofani C,
- 910 Maganuco CG, Fallet B, Ganzer L, Sironi L, Mainetti M, Ostuni R, Larimore K, Greenberg PD, de la
- Torre JC, Guidotti LG, Iannacone M. Inflammatory monocytes hinder antiviral B cell responses. Sci
- 912 Immunol. 2016;1(4).
- 913 57. Moncunill G, Scholzen A, Mpina M, Nhabomba A, Hounkpatin AB, Osaba L, Valls R, Campo
- JJ, Sanz H, Jairoce C, Williams NA, Pasini EM, Arteta D, Maynou J, Palacios L, Duran-Frigola M,
- Aponte JJ, Kocken CHM, Agnandji ST, Mas JM, Mordmuller B, Daubenberger C, Sauerwein R,

- 916 Dobano C. Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization.
- 917 Sci Transl Med. 2020;12(543).
- 918 58. van den Berg RA, Coccia M, Ballou WR, Kester KE, Ockenhouse CF, Vekemans J, Jongert E,
- 919 Didierlaurent AM, van der Most RG. Predicting RTS,S Vaccine-Mediated Protection from
- 920 Transcriptomes in a Malaria-Challenge Clinical Trial. Front Immunol. 2017;8:557.
- 921 59. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from
- 922 infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.
- 923 60. Pichichero ME. Challenges in vaccination of neonates, infants and young children. Vaccine.
- 924 2014;32(31):3886-94.

926 927 **Supplementary Material** 928 929 930 **Supplementary Methods** 931 932 Quality control of RNA sequencing data: Multidimensional scaling (MDS) plots as implemented in the 933 plotMDS function of the limma package were used to visualize variability across samples and identify 934 potential abnormalities (batch effects, outliers) or patterns of biological interest (association within 935 experimental factors). 936 937


Figure S1. Associations of month 3 levels of RTS,S/AS01 signature blood transcriptional modules (BTMs) with malaria case status in comparator recipients. Heatmap showing which of the 59 down-selected RTS,S/AS01 signature BTMs (Comparison 1) showed significantly different expression [false discovery rate (FDR)  $\leq$  0.2] in month 3 PBMC between comparator cases vs. non-malaria controls in DMSO-stimulated PBMC. Analyses were also done with Ag-stimulated PBMC but are not shown here as none of the results were significant (only DMSO had any significant BTMs). Cell color intensity represents the strength of the difference in the relevant comparison, expressed as signed  $\log_{10}$  FDR. Red, higher expression in comparator cases vs. controls; blue, lower expression in comparator cases vs. controls. High-level BTM annotation groups are shown in the left-most color bar.



## Figure S2: A) Polyfunctionality score and B) magnitude of CSP-specific CD4+ T-cell responses in RTS,S/AS01 vaccine recipients at month 3, stratified by case (clinical malaria)-control status.

950

951



956957

958959

960

Figure S3: Correlations of transcriptional and adaptive responses in comparator vaccine recipients. Heatmap showing significant correlations between month 3 levels of RTS,S/AS01 signature BTMs and month 3 antibody and cellular responses in comparator recipients. Cell color intensity represents the strength of the correlation; BTM/response pairs with significant correlations [false discovery rate (FDR)  $\leq$  0.2] are outlined in black. Cell color represents correlation direction: red, positive correlation; blue, negative correlation. High-level BTM annotation groups are shown in the left-most color bar. The bottom bar denotes the type of adaptive response analyzed (orange, antibody; purple, cellular). Green bar, IAVI measurements.






Figure S4. Correlations of Month 0 blood transcriptional module (BTM) expression with month 3 adaptive responses in RTS,S/AS01 vaccine recipients. Heatmap showing significant correlations between month 0 levels of RTS,S/AS01 signature BTMs and month 3 cellular responses (no significant correlations were seen with any month 3 antibody responses). Cell color intensity represents the strength of the correlation; BTM/response pairs with significant correlations [false discovery rate (FDR)  $\leq$  0.2] are outlined in black. Cell color represents correlation direction: red, positive correlation; blue, negative correlation. High-level BTM annotation groups are shown in the left-most color bar.



**Figure S5. RTS,S/AS01 cases tend to have higher monocyte frequencies than controls, at both baseline and at month 3.** (A) Monocyte frequencies in PBMC, (B) inflammatory monocyte counts in PBMC, and (C) ratios of inflammatory monocytes to lymphocytes. Data are shown separately in cases and in controls (RTS,S/AS01 recipients only) in each panel. (A) was assessed using FAUST; (B) and (C) were assessed using De Rosa flow immunophenotyping. "Inflammatory monocytes" refers to "HLA-DR+ CD14+CD16++" cells.



## Table S1. Antibody reagents included in the ICS panel.

984

985

Specificity	Fluorochrome	Manufacturer	Catalog Number
Live/dead	AViD*	Molecular Probes/Invitrogen	L34957
CD14	BV510*	BioLegend	301842
CD56	BUV737	BD Biosciences	564447
CD3	BV570	BioLegend	300436
CD4	BUV395	BD Biosciences	563550
CD8	BV650	BD Biosciences	563821
CD45RA	APC-H7	BD Biosciences	560674
CCR7	BV786	BioLegend	353229
CXCR5	PE-Dazzle594	BioLegend	356928
PD-1	PE-Cy7	eBioscience	25-2799-42
IFN-γ	V450	Becton Dickinson	560371
IL-2	PE	BD Biosciences	559334
IL-4	PerCP-Cy5.5	BioLegend	500822
IL-13	BV711	BD Biosciences	564288
IL-21	APC	Miltenyi Biotec	130-096-882
TNF-α	FITC	eBioscience	11-7349-82
CD40L	BV605	BioLegend	310825
Granzyme B	Alx700	BD Biosciences	560213
*AVID and CD14 are	detected in the same channel.		

Table S2. Numbers, age group, and case-control status of RTS,S/AS01 recipients by site for whom month 0 and/or month 3 PBMC samples were included in the ICS/immunophenotyping analysis.

987

988 989

		Month 0		
	Overall Total (To	tals for Bagomoyo, M	(anhiça, Lambaréné)	
	Cases		Controls	
Total	Infants	Children	Infants	Children
110 (96, 4, 10)	0(0,0,0)	24 (20, 1, 3)	0(0,0,0)	86 (76, 3, 7)
		Month 3		
	Overall Total (To	tals for Bagomoyo, M	(anhiça, Lambaréné)	
	Cases		Controls	
Total	Infants	Children	Infants	Children
304 (99, 131, 74)	35 (0, 25, 10)	31 (21, 1, 9)	133 (0, 102, 31)	105 (78, 3, 24)

994 995

996 997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

(Tables S3 through S9 are uploaded as separate Excel files) Supplementary Table Legends, Tables S3 through S9 Table S3. List of BTMs, p values, and FDRs for Comparison 1) RTS,S/AS01 vs comparator recipients at month 3 and Comparison 2) RTS.S/AS01 recipients at month 3 vs month 0. Table S4. List of all BTMs tested for significantly different expression in RTS,S/AS01 cases vs controls at month 3, along with stimulation, p value, and FDR results for each Comparison. Table S5. List of BTMs whose month 3 levels correlated significantly with at least one month 3 adaptive response variable in RTS,S/AS01 vaccinees, along with stimulation, variable details, p value, and FDR results. Table S6. List of BTMs whose month 3 or month 0 levels had significantly different expression in RTS,S/AS01 cases vs. controls in MAL067, along with p values and FDR results when testing the MAL067 sets of correlate BTMs for significantly different expression in cases vs. controls in the WRAIR 1032, MAL068 RRR, and MAL071 RRR studies. Table S7. List of BTMs whose month 0 levels correlated significantly with at least one month 3 adaptive response variable, along with stimulation, variable details, p value, and FDR results. Table S8. List of all BTMs with significantly different expression in comparator cases vs controls at month 3, along with p value and FDR results for each Comparison. Only vehicle had any significant (FDR  $\leq$  0.2) BTMs. Table S9. List of BTMs whose month 3 levels correlated significantly with at least one month 3 adaptive response variable in comparator recipients, along with stimulation, variable details, p value, and FDR results.